Denmark to drop AstraZeneca jab from Covid programme

Copenhagen becomes first national government to suspend the vaccine over suspected rare side-effects

Denmark will no longer offer the AstraZeneca vaccine as part of its immunisation programme, becoming the first country to drop the vaccine over suspected rare but serious side-effects.

The move comes in spite of strong recommendations from the World Health Organization and European medicines watchdog to continue using the inoculation, as the benefits far outweigh any potential risk.

“Denmark’s vaccination campaign will go ahead without the AstraZeneca vaccine,” the director of the Danish health authority, Søren Brostrøm, told a press conference.

Neighbouring Sweden has said it plans to pause its own roll-out of a second vaccine, produced by Johnson & Johnson, which has also been linked to rare blood clots.

Finland also announced that it would continue to limit the AstraZeneca vaccine to people aged 65 and over, adding that it was possible to give a second dose from another manufacturer and that it was drafting a plan on how to continue with its vaccinations.

Denmark’s decision comes amid a continuing focus on rare side-effects that has seen the US-produced Johnson & Johnson vaccine paused in the US over similar concerns, potentially putting back the EU’s vaccination effort by several months as it waits for supplies.

An advisory committee to the US Centers for Disease Control and Prevention was due to meet on Wednesday to review the six clotting cases and vote on recommendations for future use of the shot. The Food and Drug Administration will review the analysis.

All six cases involved women between the ages of 18 and 48, with symptoms occurring six to 13 days after vaccination. The FDA said patients should watch for up to three weeks for symptoms including severe headache, abdominal pain, leg pain or shortness of breath.

Experts said clotting risks for both vaccines remained extremely low and that vaccines were highly effective in providing protection against Covid-19. There are concerns that reports of rare side-effects could deter people from getting their shots.

The European Medicines Agency (EMA) is due to issue guidance on Johnson & Johnson next week after US federal health agencies recommended pausing use of the vaccine for at least a few days after six women under age of 50 developed blood clots following their inoculations.

Regarding AstraZeneca the European regulator found the benefits of vaccination outweighed the risks and left it to individual states to make their own assessments and decide how administer the vaccine based on local conditions, which vary widely across the bloc.

Brostrøm said last month that Denmark had “followed a precautionary principle” with regards to the AstraZeneca vaccine before this week’s decision not to use it.

Denmark was the first country in Europe to suspend the use of the AstraZeneca jab in its vaccination rollout, after reports of rare but serious cases of blood clots among those that had received the vaccine.

More than a dozen countries followed suit, but all but a few have since resumed its use after the EMA emphasised the benefits of the vaccine and deemed it “safe and effective”. As of April 4, the European Medicines Agency had received reports of 169 cases of cerebral venous sinus thrombosis (CVST) after 34m AstraZeneca doses had been administered in the European Economic Area.

In Denmark, two cases of thrombosis, one of which was fatal, were linked to vaccinations after more than 140,000 people received the jab made by the Anglo-Swedish drugmaker. In the country of 5.8 million inhabitants, 8 percent have been fully vaccinated against Covid-19, and 17 percent have received the first dose.

Although deliveries of the Johnson & Johnson shot had barely begun in Europe, questions about the two vaccines threaten to undermine public confidence in the low-cost jabs, which authorities had been counting on as a central weapon in fighting the pandemic.

The potential risk of blood clots from some vaccines has prompted different responses across Europe: French government spokesman Gabriel Attal told a news conference on Wednesday that Paris retained confidence in the AstraZeneca shot and would deploy the first doses of the newly arrived Johnson & Johnson shot.

The suspension of Johnson & Johnson’s coronavirus vaccine could delay efforts to inoculate most people in the European Union by more than two months, scientific information and analytics company Airfinity said. “If the EU can’t use the J&J vaccine indefinitely, it could push the timeline for vaccinating 75% of the population back into December,” Airfinity said in a forecast update.


Peter Beaumont

The GuardianTramp

Related Content

Article image
France limits AstraZeneca Covid jab to over-55s as Europe treads cautiously
Three Scandinavian countries reserve judgment one day after EMA says shot is safe and effectiv

Jon Henley Europe correspondent

19, Mar, 2021 @6:19 PM

Article image
Several EU countries suspend AstraZeneca vaccine to investigate blood clot cases
European Medicines Agency say ‘benefits outweigh its risks’ and vaccine can continue to be used

Jon Henley Europe correspondent

11, Mar, 2021 @4:03 PM

Article image
European countries to resume AstraZeneca jabs after safety backing
EMA says benefits outweigh risks but it is continuing to study possible link with very rare blood clotting disorder

Jon Henley and Nicola Davis

18, Mar, 2021 @7:43 PM

Article image
Italy blocks export of 250,000 AstraZeneca vaccine doses to Australia
Row continues between EU and drug firm after shortfall in vaccine deliveries to bloc

Daniel Boffey in Brussels

04, Mar, 2021 @4:53 PM

Article image
Germany vaccine body says over-65s should get AstraZeneca jab
Body updates guidance in light of studies proving vaccine’s efficacy – and endorses UK model of 12-week gap between doses

Philip Oltermann in Berlin

04, Mar, 2021 @1:18 PM

Article image
France and Germany threaten AstraZeneca over vaccine shortage
Warning of ‘legal commitment’ and concern that doses might have been diverted from the EU to the UK

Daniel Boffey in Brussels

31, Jan, 2021 @12:20 PM

Article image
EU could block millions of Covid vaccine doses from entering UK
European commission says new mechanism will give national regulators power to refuse exports

Daniel Boffey in Brussels

28, Jan, 2021 @7:41 PM

Article image
Oxford/AstraZeneca Covid vaccine given full approval by EU regulator
European Medicines Agency approves jab for use in all age groups above 18, despite German doubts

Daniel Boffey in Brussels

29, Jan, 2021 @5:58 PM

Article image
Which European states have paused AstraZeneca jabs due to clotting concerns?
Despite no evidence of a link between blood clots and the vaccine, a cautious approach is spreading

Oliver Holmes

16, Mar, 2021 @2:24 PM

Article image
EU medicines regulator to report on AstraZeneca Covid vaccine safety
Medicines agency under pressure to clear up blood clot concerns and take brakes off Europe’s vaccination drive

Jon Henley Europe correspondent

18, Mar, 2021 @5:00 AM